PE20170245A1 - Pirazinas moduladoras de gpr 6 - Google Patents
Pirazinas moduladoras de gpr 6Info
- Publication number
- PE20170245A1 PE20170245A1 PE2016001477A PE2016001477A PE20170245A1 PE 20170245 A1 PE20170245 A1 PE 20170245A1 PE 2016001477 A PE2016001477 A PE 2016001477A PE 2016001477 A PE2016001477 A PE 2016001477A PE 20170245 A1 PE20170245 A1 PE 20170245A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- pirazines
- gpr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940294P | 2014-02-14 | 2014-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170245A1 true PE20170245A1 (es) | 2017-03-30 |
Family
ID=52598823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001477A PE20170245A1 (es) | 2014-02-14 | 2015-02-13 | Pirazinas moduladoras de gpr 6 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10000468B2 (enExample) |
| EP (1) | EP3105216B1 (enExample) |
| JP (1) | JP6484640B2 (enExample) |
| KR (1) | KR20160122215A (enExample) |
| CN (1) | CN106103421B (enExample) |
| AU (1) | AU2015218402B2 (enExample) |
| BR (1) | BR112016018418A2 (enExample) |
| CA (1) | CA2939382A1 (enExample) |
| CL (1) | CL2016002043A1 (enExample) |
| CR (1) | CR20160428A (enExample) |
| DO (1) | DOP2016000211A (enExample) |
| EA (1) | EA033861B1 (enExample) |
| EC (1) | ECSP16074207A (enExample) |
| ES (1) | ES2702205T3 (enExample) |
| GE (2) | GEAP201814266A (enExample) |
| IL (1) | IL247140B (enExample) |
| MA (1) | MA39337B1 (enExample) |
| MX (1) | MX369857B (enExample) |
| MY (1) | MY184366A (enExample) |
| PE (1) | PE20170245A1 (enExample) |
| PH (1) | PH12016501613B1 (enExample) |
| UA (1) | UA117779C2 (enExample) |
| WO (1) | WO2015123533A1 (enExample) |
| ZA (1) | ZA201606077B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117779C2 (uk) * | 2014-02-14 | 2018-09-25 | Такеда Фармасьютікал Компані Лімітед | Піразини як модулятори gpr6 |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN110520127B (zh) * | 2017-03-26 | 2023-05-16 | 武田药品工业株式会社 | 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺 |
| JOP20180057A1 (ar) * | 2017-06-15 | 2019-01-30 | Takeda Pharmaceuticals Co | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| WO2021222858A1 (en) * | 2020-04-30 | 2021-11-04 | Oregon Health & Science University | Antagonists of gpr39 protein |
| WO2026032256A1 (zh) * | 2024-08-06 | 2026-02-12 | 上海齐鲁制药研究中心有限公司 | 单环类gpr6反向激动剂及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| US5563142A (en) * | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
| CN1364167A (zh) * | 1999-02-26 | 2002-08-14 | 阿瑞那制药公司 | G蛋白偶联受体6的小分子调节剂 |
| US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
| ATE307121T1 (de) | 2000-02-16 | 2005-11-15 | Neurogen Corp | Substituierte arylpyrazine |
| BR0210102A (pt) * | 2001-06-01 | 2004-06-08 | Hoffmann La Roche | Derivados de pirimidina, triazina e pirazina como receptores de glutamato |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| ES2306859T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| JPWO2004054617A1 (ja) * | 2002-12-13 | 2006-04-20 | 協和醗酵工業株式会社 | 中枢疾患の予防および／または治療剤 |
| KR20060037409A (ko) | 2003-07-30 | 2006-05-03 | 제논 파마슈티칼스 인크. | 피페라진 유도체 및 그의 치료제로서의 용도 |
| US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| EP1715867A4 (en) * | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
| US7642354B2 (en) | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| GB0414438D0 (en) * | 2004-06-28 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| US20060199828A1 (en) * | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| CN101193635A (zh) | 2005-05-13 | 2008-06-04 | 莱西肯医药有限公司 | 多环化合物及其使用方法 |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| US8495335B2 (en) * | 2006-06-16 | 2013-07-23 | Raytheon Company | Data translation system and method |
| BRPI0914891A2 (pt) | 2008-06-20 | 2015-11-24 | Metabolex Inc | agonistas de aril gpr119 e usos dos mesmos |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| EP2569302A1 (en) | 2010-05-13 | 2013-03-20 | Amgen, Inc | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| CN103221404B (zh) * | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| CA2853722A1 (en) * | 2011-10-27 | 2013-05-02 | Mayo Foundation For Medical Education And Research | Inhibiting g protein coupled receptor 6 kinase polypeptides |
| US9487526B2 (en) * | 2012-08-13 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as GPR6 modulators |
| US10329270B2 (en) | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| UA117779C2 (uk) * | 2014-02-14 | 2018-09-25 | Такеда Фармасьютікал Компані Лімітед | Піразини як модулятори gpr6 |
-
2015
- 2015-02-13 UA UAA201609102A patent/UA117779C2/uk unknown
- 2015-02-13 GE GEAP201814266A patent/GEAP201814266A/en unknown
- 2015-02-13 GE GEAP201514266A patent/GEP20186893B/en unknown
- 2015-02-13 ES ES15707836T patent/ES2702205T3/es active Active
- 2015-02-13 MX MX2016010529A patent/MX369857B/es active IP Right Grant
- 2015-02-13 CR CR20160428A patent/CR20160428A/es unknown
- 2015-02-13 CA CA2939382A patent/CA2939382A1/en not_active Abandoned
- 2015-02-13 EA EA201691632A patent/EA033861B1/ru unknown
- 2015-02-13 PE PE2016001477A patent/PE20170245A1/es unknown
- 2015-02-13 CN CN201580013589.1A patent/CN106103421B/zh active Active
- 2015-02-13 KR KR1020167025131A patent/KR20160122215A/ko not_active Ceased
- 2015-02-13 US US15/118,461 patent/US10000468B2/en not_active Expired - Fee Related
- 2015-02-13 MA MA39337A patent/MA39337B1/fr unknown
- 2015-02-13 WO PCT/US2015/015841 patent/WO2015123533A1/en not_active Ceased
- 2015-02-13 AU AU2015218402A patent/AU2015218402B2/en active Active
- 2015-02-13 EP EP15707836.1A patent/EP3105216B1/en active Active
- 2015-02-13 MY MYPI2016702927A patent/MY184366A/en unknown
- 2015-02-13 BR BR112016018418A patent/BR112016018418A2/pt not_active Application Discontinuation
- 2015-02-13 JP JP2016551806A patent/JP6484640B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-07 IL IL247140A patent/IL247140B/en active IP Right Grant
- 2016-08-12 PH PH12016501613A patent/PH12016501613B1/en unknown
- 2016-08-12 DO DO2016000211A patent/DOP2016000211A/es unknown
- 2016-08-12 CL CL2016002043A patent/CL2016002043A1/es unknown
- 2016-09-01 ZA ZA2016/06077A patent/ZA201606077B/en unknown
- 2016-09-14 EC ECIEPI201674207A patent/ECSP16074207A/es unknown
-
2018
- 2018-05-14 US US15/979,069 patent/US10273225B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141202A1 (es) | Compuesto de ciclopropanoamina | |
| PE20200292A1 (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats | |
| PE20191478A1 (es) | Compuestos moduladores del receptor de hidorcarburos de arilo (ahr) | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| CY1122127T1 (el) | Νεες ενωσεις σπειρο[3η-ινδολο-3,2-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53 | |
| PE20191479A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
| PE20161443A1 (es) | Compuestos | |
| PE20240221A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| AR061644A1 (es) | Derivados de benzofurano | |
| PE20171623A1 (es) | Agentes inmunomoduladores | |
| CL2016000581A1 (es) | Pesticidas de azol bicíclicos sustituidos por heterociclo. | |
| PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20180355A1 (es) | Desacetoxitubulisina h y analogos de esta | |
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CO6160326A2 (es) | Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| PE20120063A1 (es) | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 |